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Abstract 
Background: Multiple myeloma (MM) is the second most common hematologic malignancy 
worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE receptor 
Ig) is located on chromosome 1q23.3 and is involved in the innate immunity. Early studies have 
shown that FCER1G participates in many immune-related pathways encompassing multiple cell types. 
Meanwhile, it is associated with many malignancies. However, the relationship between MM and 
FCER1G has not been studied. 
Methods: In this study, we integrated nine independent gene expression omnibus (GEO) datasets 
and analyzed the associations of FCER1G expression and myeloma progression, ISS stage, 1q21 
amplification and survival in 2296 myeloma patients and 48 healthy donors. 
Results: The expression of FCER1G showed a decreasing trend with the advance of myeloma. As 
ISS stage and 1q21 amplification level increased, the expression of FCER1G decreased (P = 0.0012 
and 0.0036, respectively). MM patients with high FCER1G expression consistently had longer EFS and 
OS across three large sample datasets (EFS: P = 0.0057, 0.0049, OS: P = 0.0014, 0.00065, 0.0019 and 
0.0029, respectively). Meanwhile, univariate and multivariate analysis indicated that high FCER1G 
expression was an independent favorable prognostic factor for EFS and OS in MM patients (EFS: P = 
0.006, 0.027, OS: P =0.002,0.025, respectively). 
Conclusions: The expression level of FCER1G negatively correlated with myeloma progression, 
and high FCER1G expression may be applied as a favorable biomarker in MM patients. 
Key words: Multiple myeloma, FCER1G, Prognosis, Gene expression profile, Bioinformatics analysis 
Background 
Multiple myeloma (MM) is a hematologic 
malignancy characterized by the monoclonal 
expansion of bone marrow plasma cells (BMPCs) 
[1-3]. The International Staging System (ISS) divides 
MM into three categories based on the levels of 








surrogate markers of tumor burden. Additionally, 
1q21 amplification is considered a high-risk genetic 
feature, which is the most common chromosomal 
aberration in MM [4, 5]. In recent years, genetic 
biomarkers are starting to play an increasingly 
important role in the prognosis of myeloma [6, 7]. 
Therefore, it is necessary to investigate novel 
biomarkers to predict the prognosis of MM, so as to 
help improve the prognostication and treatment of 
MM. 
FCER1G is a protein coding gene located on 
chromosome 1q23.3 [8]. It has been reported that 
FCER1G interacts with other factors and participates 
in various nuclear pathways [9]. Specifically, FCER1G 
is a constitutive component of the high-affinity 
immunoglobulin E (IgE) receptor and interleukin-3 
receptor complex. It is mainly involved in mediating 
the allergic inflammatory signaling of mast cells, 
selectively mediating the production of interleukin 4 
(IL4) by basophils, and initiating the transfer from 
T-cells to the effector T-helper 2 subset [10, 11]. It also 
forms a functional signaling complex together with 
the pattern recognition receptors CLEC4D and 
CLEC4E in myeloid cells. Previous studies have 
shown that FCER1G is an innate immunity gene and 
may be involved in the development of eczema, 
meningioma and childhood leukemia [12-14]. 
FCER1G is associated with the progression of clear 
cell renal cell carcinoma (ccRCC) and may improve 
prognosis by affecting the immune-related pathways. 
In addition, FCER1G is underexpressed in acute 
myeloid leukemia [15]. Moreover, FCER1G is a critical 
molecule in signaling pathways that are widely 
involved in a variety of immune responses and cell 
types [16]. However, the prognostic role of FCER1G in 
MM remains largely unknown. 
Here, we explored the relationship between 
FCER1G expression and myeloma progression, ISS 
stage, 1q21 amplification, and survival, using the gene 
expression data of 2296 MM patients and 48 healthy 
donors. We were able to demonstrate that high 
expression of FCER1G was a good indicator of MM 
and was related to positive outcomes. 
Methods 
Data source 
In this study, we selected 2296 myeloma patients 
and 48 healthy donors from the Gene Expression 
Omnibus database (GEO). In order to assess the 
relationship between FCER1G expression and the 
prognosis of MM patients, the sample was divided 
into two cohorts. In the first cohort, there were six 
independent microarray datasets (GSE39754, 
GSE5900, GSE2113, GSE6477, GSE47552, GSE13591). 
This cohort included 48 healthy donors and 640 MM 
patients in different stages of monoclonal 
gammopathy (104 monoclonal gammopathy of 
undetermined significance (MGUS), 69 smoldering 
myeloma (SMM), 452 multiple myeloma (MM) and 15 
plasma cell leukaemia (PCL)). This cohort was used 
for microarray expression analysis. 
The second cohort consisted of three big 
independent microarray datasets of MM patients, 
GSE2658, GSE4204 and GSE24080. In GSE2658, the 
gene expression data of 559 MM patients was 
evaluated by the Affymetrix Human Genome U133 
Plus 2.0 Array. Samples in GSE4204 were 
pre-treatment bone marrow aspirates from 538 MM 
patients. In GSE24080, the gene expression profiling 
of highly purified bone marrow plasma cells was 
performed in 559 newly diagnosed MM patients. This 
cohort was mainly used for survival analysis, and the 
expression of FCER1G in different 1q21 amplification 
levels and different ISS stages was also described. 
All the samples were classified according to the 
International Myeloma Working Group criteria [17]. 
The diagnosis of MM (ICD-10 C90.0) was established 
in accordance with the World Health Organization 
guidelines[18]. The diagnosis of MGUS require more 
than 10% plasma cell infiltration in the bone marrow, 
while the levels of monoclonal protein could not 
exceed 30 g/L and there would be no evidence of 
related organ or tissue impairment (ROTI) defined as 
hypercalcemia, renal impairment, anemia, or bone 
lesions attributed to plasma-cell proliferation. SMM 
was defined with bone marrow plasmacytosis 
exceeding 10%, monoclonal protein level greater than 
30 g/L, in the absence of ROTI [19]. The diagnostic 
definition of PCL is based on Kyle’s criteria, where 
peripheral blood plasma cell absolute count greater 
than 2 × 109/L or percentage of the while blood cells 
more than 20% [20, 21].  
In GSE39754, the DNA microarray data of 
CD138+ myeloma cells from 170 newly diagnosed 
MM patients, and plasma cells (PCs) from 6 normal 
donors, were quality controlled and normalized with 
the aroma Affymetrix package. The gene expression 
level was estimated with a probe level model (PLM) 
[22]. In GSE5900, International Myeloma Working 
Group criteria were used to classify patients as having 
MGUS, SMM, or symptomatic MM [19]. In GSE6477, 
Bone marrow aspirate samples were obtained and 
enriched for CD138+ cells. In GSE64552, bone marrow 
samples were obtained from 20 patients with MGUS, 
33 with high-risk SMM and 41 with MM. All samples 
corresponded to newly diagnosed untreated patients 
[22]. In GSE2113, the gene expression profiles of 
purified plasma cells (PCs) were purified from bone 
marrow Series, after red blood cell lysis with 0.86% 




ammonium chloride, using CD138 immunomagnetic 
microbeads [22]. In GSE13591, pathological bone 
marrow specimens from 41 MM and 4 plasma cell 
leukemia (PCL) patients at diagnosis (27 
males; median age 67 years, range 46 – 85) were 
obtained. The plasma cells of the samples were 
purified ( ≥ 90%) from the bone marrow samples. 
Samples in GSE2658 and GSE4204 were pre-treatment 
bone marrow aspirates from multiple myeloma 
patients [23, 24]. The GSE24080 dataset was 
contributed by the Myeloma Institute for Research 
and Therapy at the University of Arkansas for 
Medical Sciences (UAMS, Little Rock, AR, USA). Gene 
expression profiling of highly purified bone marrow 
plasma cells was performed in newly diagnosed 
patients with MM. Plasma cells were enriched by 
anti-CD138 immunomagnetic bead selection of 
mononuclear cell fractions of bone marrow aspirates 
in a central laboratory [25].  
All clinical and molecular information and 
microarray datasets of these patients were publicly 
accessible at the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo). All experiment 
design, quality control, and data normalization were 
in line with the standard Affymetrix protocols. The 
research was conducted in accordance with the 
International Conference and the Declaration of 
Helsinki. 
Microarray analysis 
All microarray data were identified in GEO, and 
we employed statistical analysis to investigate 
significantly abnormally expressed genes on every 
microarray dataset. Briefly, gene expression data were 
obtained by using Affymetrix human Genome 133 
plus 2.0. All designs and quality control of the 
microarray experiment and data normalization were 
in line with the standard Affymetrix protocols. 
Patients with FCER1G expression values above the 
median for all MM patients were classified as 
FCER1Ghigh, and the others were considered to be 
FCER1Glow. P-value < 0.05 in unpaired t-test analysis 
and fold change (FC, log2) > 0.5 or < -0.5 was utilized 
to determine the differential expression of genes 
(DEGs). 
Statistical analysis 
All statistical analysis was performed by R 
software 3.5.0. Each dataset was first evaluated for 
normality of distribution by the Kolmogorov-Smirnov 
test to decide whether a non-parametric rank-based 
analysis or a parametric analysis should be used. The 
Fisher exact and Wilcoxon rank-sum tests were used 
to test hypotheses in categorical and continuous 
variables, respectively. The samples in the second 
cohort were divided into two groups (FCER1Ghigh, n = 
280, FCER1Glow, n = 279) based on the median 
expression values of FCER1G. Different gene 
expression analysis was performed by the limma 
package [26]. The Kaplan-Meier method and Cox 
regression multivariate analysis were used to estimate 
the survival analysis, with group comparisons made 
by using the log-rank test. Clusterprofiler package 
was used to identify GO enrichment terms and KEGG 
pathways [27]. For all statistical analysis, P-value< 
0.05 was considered significant. 
Results 
The expression level of FCER1G decreased 
with the progression of multiple myeloma 
In order to understand the expression of FCER1G 
in MM patients and other different myeloma stages, 
we employed six datasets to analyze the expression 
level of it. We observed that the expression level of 
FCER1G decreased with the progression of myeloma. 
Remarkably lower expression of FCER1G was found 
in 170 MM patients than in 6 normal donors (P = 
0.0096, Fig. 1A). In GSE5900, a significant decrease of 
FCER1G expression in Normal (n = 22), MGUS (n = 
44) and SMM (n = 12) was noticed (P = 0.0042, 0.0057, 
0.0013, severally, Fig. 1B). An obvious downtrend of 
FCER1G expression alongside the progression of 
disease was further validated in GSE6477, including 
Normal (n = 15), MGUS (n = 22), SMM (n = 24) and 
MM (n = 69) (P = 0.0016, 0.21, 0.096, 0.00013, 0.00027, 
4.3e-08, respectively, Fig. 1C). Moreover, the 
expression level of FCER1G decreased from MGUS (n 
= 20) to SMM (n = 33) and MM (n = 41), (P = 0.00051, 
0.11, 7.6e-05 severally, Fig. 1D). The same trend was 
also found in GSE2113 dataset among MGUS (n = 7), 
MM (n = 39), and PCL (n = 6) (P = 0.0059, 0.19, 0.012, 
Fig. 1E), as well as in the GSE13591 dataset including 
normal donor (n = 5), MGUS (n = 11), MM (n = 133) 
and PCL (n = 9) (Fig. 1F). In summary, the expression 
of FCER1G decreased with the evolution of 
monoclonal gammopathy, suggesting that FCER1G 
might be involved in the malignant progression of 
myeloma. 
The expression of FCER1G in MM patients 
between different ISS stages 
To further investigate the value of FCER1G 
expression, we compared the expression level of 
FCER1G at different ISS stages in 559 MM patients. A 
trend of decreasing FCER1G expression level in stages 
I, II and III (Fig. 2A, P = 0.19, 0.035, 0.00031). We also 
compared the expression of FCER1G in different 
serotypes of different ISS stages. In serum 
immunoglobulin A (IgA) group and serum immuno-




globulin G (IgG) group, the expression of FCER1G in 
stage I, II and III decreased gradually. However, there 
was no statistical significance in the serum free light 
chain (FLC) group (Fig. 2B, FLC: P = 0.41, IgA: P = 
0.0085, IgG: P = 0.014, Kruskal-Wallis test). These 
results indicated that low expression of FCER1G 
correlated with the severity of MM. 
Differences in clinical and other classic 
prognostic biomarkers in MM between 
FCER1Ghigh and FCER1Glow groups  
Using the GSE24080 dataset of 559 MM patients, 
we also analyzed the baseline characteristics between 
high and low FCER1G expression groups. We divided 
the samples into two groups based on the median 
value of FCER1G expression: FCER1Glow (n = 279) and 
FCER1Ghigh (n = 280). Between the two groups, there 
are no significant differences in the demographic 
factors, such as age, gender and race. However, 
FCER1G was more likely to be associated with isotype 
(P = 0.019), cytogenetic abnormality (P = 0.021) and 
different therapy options (P = 0.013). Additionally, the 
MM patients with low FCER1G expression were more 
likely to have a higher beta-2 microglobulin (B2M), 
creatinine (CREAT), aspirate plasma cells (ASPC) 
,bone marrow biopsy plasma cells (BMPC) and lower 
 
Figure 1. The expression level of FCER1G in several GEO datasets of Normal and myeloma patients in different stages. The X-axis represents the 
sample type, the Y-axis represent FCER1G expression level(log2). A MM patients (n= 170) compared with Normal samples (n= 6). B The different expression of 
FCER1G in Normal (n= 22), MGUS (n= 44), and SMM (n= 12). C Expression value of FCER1G in Normal (n= 15) and other different stages of 115 myeloma patients. 
MGUS (n= 22), SMM (n= 24), and MM (n= 69). D FCER1G expression level in different subtypes of myeloma patients. MGUS (n= 20), SMM (n= 33), MM (n= 41). E 
Comparison of FCER1G expression levels in 3 different stages of myeloma patients: MGUS (n= 7), MM (n= 39), and PCL (n= 6). F The correlation of FCER1G 
expression level between Normal (n= 5) and 3 different myeloma stages: MGUS (n= 11), MM (n= 133), and PCL (n= 9). 
 




hemoglobin (HGB), which were all important factors 
in MM prognosis (P< 0.001, = 0.038, < 0.001, < 0.001, = 
0.006, respectively). Moreover, the FCER1Glow group 
was more likely to have a higher expression of CDK4, 
GPRC5D, HK2, TP53 (P = 0.002, 0.001, 0.005, 0.008, 
respectively) and lower expression of WT1, CXCL12, 
DEK, CD74, DAPK3, FGFR3, XBP1, KISS1, IGHG1, 
MS4A1, RGS13, S1PR1 (P = 0.006, <0.001, <0.001, 
=0.001, =0.004, <0.001, <0.001, =0.01, <0.001, <0.001, 
<0.001, <0.001) (Table 1). 
 
Table 1. Patients’ characteristics in the GSE24080 dataset of 559 
MM patients according to FCER1G expression levels. 
  FCER1Glow, n=279 FCER1Ghigh, 
n=280 
P-value 
AGE, mean(range)  57.39(29.70-76.50) 56.97(24.83-75) 0.787 
Gender (%) female 116(41.58) 106(37.86) 0.417 
 male 163(58.42) 174(62.14)  
RACE (%) other 27(9.68) 35(12.5) 0.353 
 white 252(90.32) 245(87.5%)  
ISOTYPE (%) FLC 35(12.54) 49(17.50) 0.019 
 IgA 79(28.32) 54(19.29)  
 IgG 148(53.05) 165(58.93)  
B2M (mean(sd))  5.625(6.62) 3.842(3.53) <0.001 
CRP (mean(sd))  11.986(24.25) 11.278(21.72) 0.717 
CREAT (mean(sd))  1.434(1.46) 1.211(1.05) 0.038 
LDH (mean(sd))  173.05(69.06) 170.907(62.77) 0.701 
ALB (mean(sd))  4.033(0.58) 4.065(0.59) 0.511 
HGB (mean(sd))  11.042(1.84) 11.464(1.76) 0.006 
ASPC (mean(sd))  46.779(23.63) 38.431(24.36) <0.001 
BMPC (mean(sd))  52.49(25.53) 40.262(25.63) <0.001 
MRI (mean(sd))  11.197(14.65) 10.872(14.44) 0.799 
Cytogenetic 
abnormality (%) 
No 162(58.06) 190(67.86) 0.021 
 Yes 117(41.94) 90(32.14)  
High CCND1, no 
(%) 
 130(46.59) 150(53.57) 0.118 
High WT1, no (%)  123(44.09) 157(56.07) 0.006 
High CXCL12, no 
(%) 
 71(25.45) 209(74.64) <0.001 
High DEK, no (%)  107(38.35) 173(61.79) <0.001 
High CD74, no (%)  119(42.65) 161(57.5) 0.001 
High NRAS, no (%)  143(51.25) 137(48.93) 0.642 
High CDK4, no (%)  159(56.99) 121(43.21) 0.002 
High BRAF, no (%)  150(53.76) 130(46.43) 0.099 
High LIG4, no (%)  134(48.03) 146(52.14) 0.374 
High GPRC5D, no 
(%) 
 160(57.35) 120(42.86) 0.001 
High DAPK3, no (%)  122(43.73) 158(56.43) 0.004 
High FGFR3, no (%)  105(37.63) 175(62.5) <0.001 
High XBP1, no (%)  116(41.58) 164(58.57) <0.001 
High KISS1, no (%)  124(44.44) 156(55.71) 0.01 
High PTPN11, no 
(%) 
 139(49.82) 141(50.36) 0.966 
High IDH2, no (%)  144(51.61) 136(48.57) 0.526 
High HRAS, no (%)  139(49.82) 141(50.36) 0.966 
High HK2, no (%)  157(56.27) 123(43.93) 0.005 
High IGHG1, no (%)  109(39.07) 171(61.07) <0.001 
High MS4A1, no (%)  110(39.43) 170(60.71) <0.001 
High RGS13, no (%)  115(41.22) 165(58.93) <0.001 
High RRAS2, no (%)  131(46.95) 149(53.21) 0.163 
High S1PR1, no (%)  112(40.14) 168(60) <0.001 
High TP53, no (%)  156(55.91) 124(44.29) 0.008 
Therapy (%) TT2 187(67.03) 158(56.43) 0.013 
 TT3 92(32.97) 122(43.57)  
AGE: Age at registration (years); B2M: Beta-2 microglobulin, mg/l; CRP: C-reactive 
protein, mg/l; CREAT: Creatinine, mg/dl; LDH: Lactate dehydrogenase, U/l; ALB: 
Albumin, 35 g/l; HGB: Haemoglobin, g/dl; ASPC: Aspirate plasma cells (%); 
BMPC: Bone marrow biopsy plasma cells (%); MRI: Number of magnetic resonance 
imaging (MRI)- defined focal lesions (skull, spine, pelvis); Cytogenetic abnormality: 
An indicator of the detection of cytogenetic abnormalities; no: number of patients. 
Prognostic value of FCER1G expression in MM 
By using the Cox regression model, we 
computed multivariate hazard ratios for different 
variables of 559 MM patients. Univariate analysis 
results showed that FCER1G and albumin (ALB), 
beta-2 microglobulin (B2M), bone marrow biopsy 
plasma cells (BMPC), hemoglobin (HGB), number of 
magnetic resonance imaging (MRI) were all closely 
related to EFS and OS with significant P values (Table 
2). Furthermore, in multivariate analysis for EFS, the 
hazard ratio of hemoglobin was 0.66 (P = 0.023), while 
the hazard ratio of FCER1G expression was 0.7 (P = 
0.024). These two factors were significantly related to 
the EFS in MM patients. For OS, the hazard ratio of 
beta-2 microglobulin was 1.66 (P = 0.007) and the 
hazard ratio of FCER1G expression was 0.69 (P = 0.02), 
indicating that both had a close association with OS. 
The hazard ratio of albumin and number of magnetic 
resonance imaging were 0.58 and 1.93 (P = 0.001, 
<0.001). FCER1G expression value was a stable factor 
affecting the survival level of MM patients (Table 3). 
 
Table 2. Univariate analysis for EFS and OS. 
Variables EFS OS 
 HR(95%CI) P-value HR(95%CI) P-value 
FCER1G(high vs. low) 0.65(0.48-0.88) 0.006 0.62(0.45-0.84) 0.002 
AGE(≥60 vs. <60) 0.97(0.71-1.32) 0.839 1.4(1.04-1.89) 0.028 
Gender 1.05(0.77-1.43) 0.75 0.97(0.72-1.32) 0.85 
ALB 0.76(0.56-1.02) 0.071 0.49(0.36-0.67) < 0.001 
B2M 1.72(1.27-2.33) < 0.001 2.21(1.64-3) < 0.001 
BMPC 1.63(1.18-2.27) 0.003 1.82(1.29-2.56) 0.001 
HGB 0.54(0.39-0.74) < 0.001 0.62(0.45-0.84) 0.002 
MRI 1.26(0.93-1.71) 0.141 1.9(1.38-2.61) < 0.001 
EFS: event-free survival; OS: overall survival; CR: complete remission; HR: hazard 
ratio; CI: confidence interval; ALB: Albumin(35 g/l); B2M: Beta-2 
microglobulin(mg/l); BMPC: Bone marrow biopsy plasma cells (%); HGB: 
Haemoglobin(g/dl); MRI: Number of magnetic resonance imaging (MRI)- defined 
focal lesions (skull, spine, pelvis). 
 
The expression of FCER1G in different 
amplification levels of 1q21 
1q21 amplification is associated with poor 
prognosis, and FCER1G is located on chromosome 
1q23.3. We compared FCER1G expression level under 
the different amplification of 1q21. There was a 
statistically significant difference of the expression 
levels between different levels of 1q21 amplification. 
The expression of FCER1G was decreased with the 
amplification of 1q21 (Fig. 3A, P = 0.0036, Kruskal- 
Wallis test). 
FCER1G predicts the survival level in MM 
From all the results above, we could assume that 
the low expression of FCER1G was related to adverse 
outcomes of MM. Thus, we further analyzed the 
survival level in the second cohort. We found that the 
FCER1Glow group had significantly shorter OS 




compared to the FCER1Ghigh group in two 
independent datasets of GSE2658 and GSE4204 (Fig. 
4A and B, P = 0.0014, 0.00065, respectively). The same 
prognostic value of FCER1G in MM was also found in 
GSE24080 (Fig. 4C and D, OS, P = 0.0019, EFS, P = 
0.0057). Likewise, the survival level retains similar 
results at the milestone points of Year 2008 (Fig. 4E 
and F, OS, P = 0.0029, EFS, P = 0.0049).  
 
 
Figure 2. The expression of FCER1G in different ISS stages of MM patients. The X-axis represents the ISS stage while the Y-axis represents FCER1G 
expression value(log2). A The expression level of FCER1G had a decreasing trend with the ISS stage increases, Kruskal-Wallis test. B FCER1G expression pattern in 
different serotypes. FLC, P= 0.41, IgA, P= 0.0085, IgG, P= 0.014 respectively, Kruskal-Wallis test. 




Table 3. Multivariate analysis for EFS and OS 
Variables EFS OS 
 HR(95%CI) P-value HR(95%CI) P-value 
FCER1G(high vs. low) 0.7(0.51-0.95) 0.024 0.69(0.51-0.94) 0.02 
AGE(≥60 vs. <60) 0.91(0.66-1.24) 0.549 1.3(0.96-1.76) 0.086 
Gender 1.13(0.82-1.54) 0.451 0.99(0.73-1.34) 0.949 
ALB 0.85(0.62-1.16) 0.313 0.58(0.42-0.79) 0.001 
B2M 1.26(0.88-1.82) 0.209 1.66(1.15-2.39) 0.007 
BMPC 1.31(0.91-1.88) 0.145 1.34(0.92-1.96) 0.13 
HGB 0.66(0.46-0.94) 0.023 0.95(0.67-1.34) 0.756 
MRI 1.3(0.96-1.77) 0.095 1.93(1.4-2.65) < 0.001 
EFS: event-free survival; OS: overall survival; CR: complete remission; HR: hazard 
ratio; CI: confidence interval; ALB: Albumin, 35 g/l; B2M: Beta-2 microglobulin, 
mg/l; BMPC: Bone marrow biopsy plasma cells (%); HGB: Haemoglobin, g/dl; 
MRI: Number of magnetic resonance imaging (MRI)- defined focal lesions (skull, 
spine, pelvis). 
 
Different expression and pathway analysis for 
DEGs of FCER1Ghigh versus FCER1Glow 
In order to find the genes associating with 
FCER1G, we analyzed the differential expression 
values of FCER1Ghigh versus FCER1Glow. As many as 
709 genes were up-regulated and 14 genes were 
down-regulated (P< 0.05, (FC, log2)> 0.5 or < -0.5, Fig. 
5A). Heatmap showed the top 15 up-regulated genes 
and 14 down-regulated genes (Fig. 5B). By using the 
DEGs, we analyzed the enriched GO terms and KEGG 
pathways. Among the biological process terms of GO, 
most of DEGs were enriched in leukocyte migration 
(GO:0050900), cell chemotaxis (GO:0060326), humoral 
immune response (GO:0006959), and regulation of 
inflammatory response (GO:0050727) (Fig. 5C). In the 
KEGG analysis results, Staphylococcus aureus 
infection (hsa05150), Systemic lupus erythematosus 
(hsa05322) and complement and coagulation cascades 




Figure 3. The expression of FCER1G in different amplification levels of 1q21. The X-axis represents the 1q21 amplification, the Y-axis represents the 
FCER1G expression level. A FCER1G expression levels at different amplification levels of 1q21 in 248 MM patients. The expression value was measured as log2. P= 
0.022, Kruskal-Wallis test. 




Module screening from the PPI network 
Finally, all the top 29 DEGs of FCER1Ghigh versus 
FCER1Glow were used to calculate the correlativity 
between those genes (Fig. 6A). We also screened the 
protein-protein interaction (PPI) network in the String 
database by using the top 29 DEGs [28]. Most of the 
up-regulated genes and two down-regulated genes 
(MYC and HIST1H2AD) were interactional in the PPI 
network (Fig. 6B). Then we discovered two sub- 
networks by using MCODE in Cytoscape (Fig. 6C, D). 
In the PPI network, C1QB, C1QA, C1QC, CD163, 
CD14, S100A8, S100A9, LTF, LYZ and FCGR3A were 
all reported to be associated with MM in early 
research. FCER1G acts as a core gene in both the 
general network and two subnetworks. 
 
Figure 4. Survival analysis of FCER1Ghigh and FCER1Glow group. The X-axis represents the survival time(month) and the Y-axis represents survival probability. 
Kaplan-Meier survival curves showed that FCER1Ghigh predicts good endpoint in both event-free survival time (EFS) and overall survival (OS), Log-rank test. A OS 
between FCER1Ghigh and FCER1Glow in GSE2658 dataset with P= 0.0014. B OS analysis in GSE2404 of 538 pre-treatment MM patients with P= 0.00065. C, D The 
survival analysis of EFS and OS in FCER1Ghigh and FCER1Glow groups of 559 MM patients in GSE24080 dataset. EFS: P= 0.0057, OS: P= 0.0019. E, F The EFS and OS 
results at the milestone points of 2008 in GSE24080 with P= 0.0049, P= 0.0029 respectively. 





Figure 5. Different expression genes (DEGs) and the results of GO enrichment and KEGG pathway analysis. A Volcano plot of the DEGs expression 
between FCER1Ghigh and FCER1Glow. Cut-off criteria for DEGs significance was P< 0.05 and the absolute value of the log2 fold change> 0.5. The Y-axis displays the 
-log10 P-value for each gene, while the X-axis displays the log2 fold change for that gene relative to FCER1G expression. Green dots represent 14 down-regulated 
genes, the red circle represents 709 up-regulated genes, and black dots indicate non-significance genes. B Heatmap shows top 15 up-regulated genes and top 14 
down-regulated genes. The red represents high expression, the white represents intermediate expression, and the blue represents low expression. C, D GO and 
KEGG results for differential expression genes. The X-axis represents gene ratio and the Y-axis represents different enriched pathways. 
 
Discussion 
Our research demonstrated that the expression 
level of FCER1G showed a decreasing trend in the 
deterioration of plasma cell malignancy. Higher 
expression of FCER1G in MM patients was 
associated with favorable prognosis. Likewise, the 
GO and KEGG pathways mainly enriched in 
defense response, immune response, and 
inflammatory response. PPI network also revealed 
that many cancer-associated genes interacted with 
FCER1G. All of these results show that FCER1G 
may be a tumor suppressor gene in myeloma. 
Early studies found that FCER1G transduced 
activation signals from various immunoreceptors 
[10, 29]. It was functionally linked to mediate 
neutrophil activation and was also involved in 
platelet activation. Associated diseases included 
Bleeding Disorder, Platelet-Type, 11(BDPLT11) and 
Mitochondrial Complex I Deficiency. FCER1G also 
engaged in many immune responses and played a 
tumor-promoting role in many kinds of tumors, 




such as meningioma, Clear cell renal cell carcinoma 
(ccRCC), childhood leukemia and Acute Myeloid 
Leukemia(AML) [12, 14, 15, 30]. It was also reported 
that the demethylation of FCER1G was induced by 
IL15 in the NKp30+CD8+ T cell population 
exhibiting high natural killer-like antitumor 
potential [31]. FCER1G inhibits the expression of 
certain Alzheimer's disease susceptibility genes by 
participating in Herpes simplex (HSV-1) escape 
strategy [9]. Interestingly, the abundant expression 
of FCER1G was found in the circulating tumor cells 
of a prostate cancer patient who was sensitive to 
docetaxel chemotherapeutic reagent [32]. 
 
 
Figure 6. The Correlation analysis and PPI results of DEGs. A The correlation analysis of DEGs with the Pearson correlation coefficient, the red circle means 
positive correlation while green means negative correlation. B PPI network of top DEGs of top 15 up-regulated genes and 14 down-regulated genes. C, D 
Sub-networks analysis of the PPI network by using MCODE APP in Cytoscape. 




In the PPI network, many important genes that 
were associated with MM had been screened. S100A9 
was reported significantly down-regulated in MM 
patients and further support MM survival by 
stimulating angiogenesis and cytokine secretion [33, 
34]. S100A9 was directly implicated in promoting 
Myeloid-derived suppressor cells (MDSC), which 
plays a critical role in the MM progression and can be 
considered as a therapeutic target in this disease [35]. 
C1QB, C1QA, and C1QC were all the complement c1q 
chains. Early reports showed that complement c1q 
acts in the tumor micro environment as a 
cancer-promoting factor independently of 
complement activation [36]. LTF has identified as a 
Cereblon (CRBN) binding protein and established 
relevance to MM biology [37]. LYZ was found as an 
element of the 9-genes prognostic signature and 
might be an independent prognostic factor in patients 
with multiple myeloma [38]. HLA-DRA plays an 
important role in bone lesions common in MM 
patients by participating in the immune response 
activation pathway [39]. CD163 is a tumor-associated 
macrophage marker, the high level of Monocyte/ 
macrophage-derived soluble CD163 was associated 
with higher stage according to the ISS and with other 
known prognostic factors in multiple myeloma [40, 
41]. MYC activation is associated with hyperdiploid 
MM and shorter survival, and also plays a causal role 
in the progression of monoclonal gammopathy to 
multiple myeloma. MYC protein overexpression is a 
feature of progression and adverse prognosis in 
multiple myeloma [42-45]. In recent research, it was 
also proved that sialyltransferase inhibition leads to 
inhibition of tumor cell interactions with VCAM1, and 
improves survival in a human multiple myeloma 
mouse model [46]. FCGR3A was proved to be 
associated with anti-tumor response. [47]. The 
polymorphisms of FCGR3A play an important role in 
First-Relapsed ovarian cancer, metastatic breast 
cancer, and metastatic colorectal cancer [48-51]. Early 
research also found that FCGR3A was associated with 
infections of MM patients [52].  
The PPI results showed that FCER1G was a hub 
gene in the network and directly interact with many 
MM associated genes. As we demonstrated 
previously, downregulation of FCER1G expression 
was closely related to the deterioration of myeloma. 
Combined with GO and KEGG analysis results above, 
FCER1G might interact with other MM associated 
genes and was mainly involved in leukocyte 
migration, cell chemotaxis, and immune and 
inflammatory response pathway, and therefore 
exerted an anti-cancer effect in multiple myeloma. 
Conclusions 
To sum up, we have clearly demonstrated that 
high FCER1G expression was a good prognostic factor 
in MM patients. The expression level of FCER1G 
decreased with the progression of myeloma. 
Moreover, GO term enrichment, KEGG pathways, 
and PPI networks involved in MM provided insights 
into the pathogenesis processes associated with 
varying FCER1G expression. The underexpression of 
FCER1G could serve as a promising therapeutic target 
for MM patients.  
However, in this research, the exact 
pathophysiologic role of FCER1G in myeloma cells 
was not been fully demonstrated. Further studies 
including the molecular mechanism and deeper 
genomic research of FCER1G in myeloma 
deterioration will be urgently required. 
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